Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified

Loading news article.

Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified | WAPE

Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified

Article summary

Related companies

Comments —